Cancer stem cells: a new approach to tumor development

Imagem de Miniatura
Arquivos
art_KOBAYASHI_Cancer_stem_cells_a_new_approach_to_tumor_2015.PDF (155.89 KB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2015
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC MEDICA BRASILEIRA
Autores
KOBAYASHI, Natalia Cristina Ciufa
Citação
Revista da Associacao Medica Brasileira, v.61, n.1, p.86-93, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Many theories have been proposed to explain the origins of cancer. Currently, evidences show that not every tumor cell is capable of initiating a tumor. Only a small part of the cancer cells, called cancer stem cells (CSCs), can generate a tumor identical to the original one, when removed from human tumors and transplanted into immunosuppressed mice. The name given to these cells comes from the resemblance to normal stem cells, except for the fact that their ability to divide is infinite. These cells are also affected by their microenvironment. Many of the signaling pathways, such as Wnt, Notch and Hedgehog, are altered in this tumoral subpopulation, which also contributes to abnormal proliferation. Researchers have found several markers for CSCs; however, much remains to be studied, or perhaps a universal marker does not even exist, since they vary among tumor types and even from patient to patient. It was also found that cancer stem cells are resistant to radiotherapy and chemotherapy. This may explain the re-emergence of the disease, since they are not completely eliminated and minimal amounts of CSCs can repopulate a tumor. Once the diagnosis in the early stages greatly increases the chances of curing cancer, identifying CSCs in tumors is a goal for the development of more effective treatments. The objective of this article is to discuss the origin of cancer according to the theory of stem cell cancer, as well as its markers and therapies used for treatment.
Palavras-chave
neoplastic stem cells, biological tumor markers, SCID, mice, local neoplasm recurrence
URI
https://observatorio.fm.usp.br/handle/OPI/9911
Referências
  1. Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014
  2. Britton Kelly M, 2011, Cancers (Basel), V3, P2106, DOI 10.3390/cancers3022106
  3. Chen X, 2013, CELL CYCLE, V12, P579, DOI 10.4161/cc.23721
  4. Cheng L, 2010, BIOCHEM PHARMACOL, V80, P654, DOI 10.1016/j.bcp.2010.04.035
  5. Dirks PB, 2008, PHILOS T R SOC B, V363, P139, DOI 10.1098/rstb.2006.2017
  6. Ebben JD, 2010, EXPERT OPIN THER TAR, V14, P621, DOI 10.1517/14712598.2010.485186
  7. Economopoulou P, 2012, ONCOLOGIST, V17, P1394, DOI 10.1634/theoncologist.2012-0163
  8. Fanali C, 2014, WORLD J GASTROENTERO, V20, P923, DOI 10.3748/wjg.v20.i4.923
  9. Horton SJ, 2012, HAEMATOL-HEMATOL J, V97, P966, DOI 10.3324/haematol.2011.054734
  10. Huang EH, 2008, TRENDS MOL MED, V14, P503, DOI 10.1016/j.molmed.2008.09.005
  11. Iovanna J, 2012, FRONT ONCOL, V02, P01
  12. Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
  13. Krishnamurthy S, 2012, J DENT RES, V91, P334, DOI 10.1177/0022034511423393
  14. Kwon MJ, 2013, INT J MOL SCI, V14, P6624, DOI 10.3390/ijms14046624
  15. Lang SH, 2009, J PATHOL, V217, P299, DOI 10.1002/path.2478
  16. Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003
  17. Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118
  18. Li J, 2010, AAPS J, V12, P223, DOI 10.1208/s12248-010-9181-5
  19. Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986
  20. Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070
  21. Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193
  22. O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824
  23. Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100
  24. Penchev VR, 2012, CLIN CANCER RES, V18, P4277, DOI 10.1158/1078-0432.CCR-11-3112
  25. Puglisi MA, 2013, WORLD J GASTROENTERO, V19, P2997, DOI 10.3748/wjg.v19.i20.2997
  26. Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
  27. Rich JN, 2008, COLD SH Q B, V73, P411, DOI 10.1101/sqb.2008.73.060
  28. Saad ED, 2002, REV BRAS CANCEROL, V48, P555
  29. Sanders MA, 2011, FRONT BIOSCI-LANDMRK, V16, P1651, DOI 10.2741/3811
  30. Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
  31. Schatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.x
  32. Schulenburg A, 2006, CANCER, V107, P2512, DOI 10.1002/cncr.22277
  33. Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064
  34. Sell S, 2009, STEM CELLS CANC, P1, DOI 10.1007/978-0-387-89611-3_1
  35. Shackleton M, 2010, MOL ONCOL, V4, P451, DOI 10.1016/j.molonc.2010.06.006
  36. Soltysova A, 2005, NEOPLASMA, V52, P432
  37. Subramaniam D, 2010, MINI-REV MED CHEM, V10, P359
  38. Sullivan JP, 2010, CANCER METAST REV, V29, P61, DOI 10.1007/s10555-010-9216-5
  39. Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20
  40. Wang B, 2011, GENOME MED, V3, DOI 10.1186/gm225
  41. Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
  42. Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024
  43. Zhan QL, 2013, BIOMED RES INT, DOI 10.1155/2013/916819
  44. Zhang ZC, 2012, ORAL ONCOL, V48, P1, DOI 10.1016/j.oraloncology.2011.10.004

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - ODS/03